What is Drug Utilization Review (DUR)?

Drug Utilization Review (DUR) is an authorized, structured, ongoing review of prescribing, dispensing, and use of medication. It assesses the appropriateness, safety, and effectiveness of drug therapy to improve patient outcomes and detect potential issues like drug interactions, overutilization, or underutilization.

What are the three main types of DUR?

The three main types are Prospective DUR (performed before medication dispensing), Concurrent DUR (performed during the course of treatment, often in institutional settings), and Retrospective DUR (performed after the medication has been dispensed and used, analyzing patterns over time).

What is the primary federal law mandating Prospective DUR?

The Omnibus Budget Reconciliation Act of 1990 (OBRA '90) is the primary federal law that mandates Prospective DUR for Medicaid patients, requiring pharmacists to review prescriptions for potential problems before dispensing and offer patient counseling.

What specific issues does Prospective DUR typically screen for?

Prospective DUR screens for a wide range of issues including drug-drug interactions, drug-allergy interactions, contraindications, therapeutic duplication, incorrect dosage or duration, drug-disease contraindications, and potential for abuse or misuse.

Who is primarily responsible for conducting Prospective DUR in community pharmacy?

The licensed pharmacist is primarily responsible for conducting Prospective DUR in community pharmacy settings, as mandated by federal and state laws, to ensure the safety and appropriateness of medication therapy before it reaches the patient.

What is the role of a DUR Board or Committee?

DUR Boards or Committees, often established at the state level (e.g., for Medicaid programs) or within healthcare organizations (e.g., P&T committees), analyze retrospective DUR data to develop educational interventions, refine prescribing guidelines, and improve overall drug utilization patterns.

How does DUR contribute to cost-effectiveness in healthcare?

By identifying and preventing inappropriate or unnecessary drug use, DUR helps reduce healthcare costs associated with adverse drug events, hospitalizations, and wasteful spending on ineffective therapies, ultimately optimizing resource allocation.

Drug Utilization Review (DUR) Processes and Standards for the MPJE Multistate Pharmacy Jurisprudence Examination

Introduction to Drug Utilization Review (DUR) for the MPJE

As an aspiring pharmacist preparing for the MPJE Multistate Pharmacy Jurisprudence Examination, understanding Drug Utilization Review (DUR) processes and standards is not just an academic exercise—it's fundamental to your future practice and a critical component of patient safety. DUR represents a pharmacist's legal and ethical responsibility to ensure that medication therapy is appropriate, safe, and effective. This mini-article will dissect DUR, outlining its various forms, legal underpinnings, and practical implications, all while highlighting its relevance for your MPJE success.

The MPJE frequently tests a candidate's grasp of federal and state laws governing pharmacy practice. DUR is a prime example of an area where federal mandates (like OBRA '90) intertwine with specific state regulations. A solid understanding here demonstrates not only your knowledge of the law but also your commitment to fulfilling the pharmacist's crucial role in medication management and patient care.

Key Concepts in Drug Utilization Review

DUR is broadly categorized into three types, each serving a distinct purpose in the continuum of patient care. Understanding these categories is essential for the MPJE.

1. Prospective DUR (P-DUR)

Definition: Prospective DUR is the review of drug therapy before a prescription is dispensed or administered. It is the most immediate and hands-on form of DUR, primarily performed by the dispensing pharmacist.

Legal Mandate: The Omnibus Budget Reconciliation Act of 1990 (OBRA '90) is the cornerstone federal legislation that mandated Prospective DUR for all Medicaid patients. While initially for Medicaid, most states have extended these requirements to all patients, regardless of payer.
Pharmacist's Role: The pharmacist is legally and professionally obligated to identify and resolve potential drug-related problems before the patient receives the medication. This involves a comprehensive review of the patient's medication profile and the new prescription.
Common Issues Screened:
- Drug-Drug Interactions: Detecting potential harmful interactions between prescribed medications.
- Drug-Allergy Interactions: Ensuring the patient is not allergic to the prescribed drug.
- Drug-Disease Contraindications: Identifying if the drug is contraindicated due to an existing medical condition.
- Therapeutic Duplication: Preventing the use of multiple drugs from the same therapeutic class for the same indication, which can increase side effects without added benefit.
- Incorrect Dosage or Duration: Checking if the dose, frequency, or duration of therapy is appropriate for the patient's age, weight, renal/hepatic function, and condition.
- Route of Administration: Verifying the prescribed route is appropriate and safe.
- Abuse/Misuse: Identifying potential patterns of drug abuse or fraud.
- Underutilization/Overutilization: Detecting instances where a patient may not be receiving necessary therapy or receiving too much.
Intervention: If a potential problem is identified, the pharmacist must intervene, which may involve contacting the prescriber for clarification or modification, or counseling the patient on safe and effective use. Documentation of these interventions is crucial.

2. Concurrent DUR (C-DUR)

Definition: Concurrent DUR involves the ongoing review of drug therapy during the course of treatment. This type of DUR is most commonly seen in institutional settings (hospitals, long-term care facilities) where patients are receiving multiple medications and their conditions are closely monitored.

Pharmacist's Role: In institutional settings, clinical pharmacists often perform C-DUR by reviewing patient charts, laboratory values, and medication administration records to ensure therapy remains appropriate as the patient's condition evolves.
Examples: Monitoring for adverse drug reactions, adjusting doses based on renal function changes, ensuring appropriate use of antibiotics based on culture results, or discontinuing medications no longer needed.

3. Retrospective DUR (R-DUR)

Definition: Retrospective DUR is the review of drug therapy after the medication has been dispensed and used. This type of DUR analyzes patterns of drug use over a period, typically on a population level, to identify trends, improve prescribing habits, and develop educational programs.

Performed By: Often conducted by state Medicaid agencies, managed care organizations, or Pharmacy and Therapeutics (P&T) committees within healthcare systems. State DUR boards, as mandated by OBRA '90 for Medicaid programs, play a significant role here.
Purpose:
- Quality Improvement: Identifying patterns of suboptimal prescribing or dispensing that can be addressed through educational interventions for prescribers and pharmacists.
- Cost-Effectiveness: Analyzing drug utilization to identify areas of waste or opportunities for more cost-effective therapy.
- Fraud and Abuse Detection: Detecting patterns indicative of potential fraud, waste, or abuse.
- Developing Guidelines: Informing the creation of prescribing guidelines, formularies, or prior authorization criteria.
Data Sources: Claims data, patient profiles, electronic health records.

The Role of State DUR Boards and Committees

OBRA '90 requires each state to establish a DUR Board (or similar committee) for its Medicaid program. These boards are typically composed of physicians and pharmacists and are responsible for:

Establishing standards for R-DUR.
Reviewing data and identifying patterns of inappropriate drug use.
Developing and implementing educational programs for providers.
Providing recommendations to state Medicaid agencies regarding drug coverage and policies.

How DUR Appears on the MPJE Exam

The MPJE will test your understanding of DUR through various question styles, often focusing on practical application and legal compliance. Expect scenario-based questions that require you to apply your knowledge to real-world pharmacy situations.

Scenario-Based Questions: You might be presented with a patient profile and a new prescription, then asked what DUR issues a pharmacist should identify and what action should be taken. For example: "A patient with a known penicillin allergy presents a prescription for amoxicillin. What is the pharmacist's primary responsibility under Prospective DUR?"
Identification of DUR Types: Questions may ask you to distinguish between prospective, concurrent, and retrospective DUR based on a given description of an activity.
Legal Mandates: Expect questions directly related to OBRA '90 requirements, especially concerning Prospective DUR, patient counseling, and the maintenance of patient profiles. Know that while OBRA '90 specifically covers Medicaid, many state laws expand these requirements to all patients.
Pharmacist's Responsibilities: The exam will often focus on the specific duties of the pharmacist when a DUR alert is triggered. This includes the requirement to intervene, document, and potentially contact the prescriber.
Ethical Dilemmas: Some questions may present situations where legal requirements intersect with ethical considerations, prompting you to choose the most appropriate and compliant course of action.

For more specific examples and to test your knowledge, consider exploring MPJE Multistate Pharmacy Jurisprudence Examination practice questions or our free practice questions.

Study Tips for Mastering DUR on the MPJE

To effectively prepare for DUR questions on the MPJE, adopt a structured and practical study approach:

Master OBRA '90: Understand its core requirements, particularly regarding Prospective DUR, patient counseling, and patient profiles. This federal law is the foundation upon which state DUR laws are built.
Differentiate the Three DUR Types: Create a table or flashcards to clearly distinguish between prospective, concurrent, and retrospective DUR. Focus on when they occur, who performs them, and their primary purpose.
Understand the "Why": Don't just memorize what DUR is; understand its importance for patient safety, public health, and the pharmacist's professional accountability.
Focus on Pharmacist Action: For Prospective DUR, specifically, know the steps a pharmacist must take when an alert is triggered. What is the hierarchy of intervention? When must the prescriber be contacted? What documentation is necessary?
Review State-Specific Laws: While OBRA '90 sets the federal baseline, your specific state's Board of Pharmacy regulations may expand upon or provide additional requirements for DUR. Be aware of these nuances for the state where you intend to practice.
Practice with Scenarios: Work through as many practice questions as possible that present realistic pharmacy scenarios. This will help you apply your knowledge rather than just recall facts. Pay attention to the details in the scenarios.
Create Mnemonics: If you struggle with lists of DUR issues (e.g., drug-drug, drug-allergy, etc.), create mnemonics to help recall them quickly during the exam.

Common Mistakes to Watch Out For

Candidates often make specific errors when tackling DUR questions on the MPJE. Being aware of these can help you avoid them:

Confusing DUR Types: A common mistake is misidentifying whether a given scenario describes prospective, concurrent, or retrospective DUR. For example, confusing a claims data analysis (retrospective) with a real-time interaction check (prospective).
Ignoring OBRA '90: Underestimating the importance of OBRA '90 and its specific mandates, particularly for Medicaid patients. Even if your state extends DUR to all patients, the federal law is still the foundational requirement.
Failing to Act: In scenario questions, candidates sometimes fail to select the most appropriate and legally compliant action. Remember, a DUR alert typically requires an intervention, not just an observation.
Overlooking Documentation: Forgetting the critical importance of documenting DUR interventions and resolutions. Proper documentation is a legal requirement and protects the pharmacist.
Not Considering All Relevant Information: In complex scenarios, overlooking a piece of patient information (e.g., age, renal function, existing medical conditions) that would trigger a DUR alert.
Assuming Uniformity: Assuming all states have identical DUR requirements. While OBRA '90 sets a baseline, state laws can and do vary, often expanding on federal mandates.

Quick Review / Summary

Drug Utilization Review is a cornerstone of safe and effective pharmacy practice, ensuring that patients receive appropriate medication therapy while detecting and preventing potential drug-related problems. For the MPJE, remember these key takeaways:

Prospective DUR: Performed before dispensing, primarily by the pharmacist, mandated by OBRA '90 (for Medicaid, often extended by states) to identify and resolve immediate issues.
Concurrent DUR: Performed during treatment, typically in institutional settings, for ongoing monitoring.
Retrospective DUR: Performed after therapy, analyzing patterns over time for quality improvement, cost-effectiveness, and policy development, often by state DUR boards or P&T committees.
Pharmacist's Responsibility: Central to Prospective DUR, involving a thorough review, intervention when necessary, and meticulous documentation.
MPJE Focus: Expect scenario-based questions testing your ability to identify DUR issues, apply legal mandates (especially OBRA '90), and determine appropriate pharmacist actions.

By thoroughly understanding these concepts, you'll not only be well-prepared for the MPJE but also equipped to uphold the highest standards of patient care in your professional career.